Private Trust Co. NA Cuts Position in Zoetis Inc. $ZTS

Private Trust Co. NA decreased its position in Zoetis Inc. (NYSE:ZTS) by 1.1% during the 2nd quarter, Holdings Channel reports. The fund owned 8,092 shares of the company’s stock after selling 87 shares during the quarter. Private Trust Co. NA’s holdings in Zoetis were worth $1,262,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Angeles Wealth Management LLC raised its holdings in shares of Zoetis by 125.7% in the 2nd quarter. Angeles Wealth Management LLC now owns 3,713 shares of the company’s stock valued at $579,000 after purchasing an additional 2,068 shares in the last quarter. SilverOak Wealth Management LLC grew its stake in shares of Zoetis by 6.2% during the second quarter. SilverOak Wealth Management LLC now owns 3,750 shares of the company’s stock worth $585,000 after purchasing an additional 219 shares in the last quarter. Oxbow Advisors LLC increased its holdings in Zoetis by 3.5% in the second quarter. Oxbow Advisors LLC now owns 28,801 shares of the company’s stock valued at $4,492,000 after buying an additional 967 shares during the last quarter. Nordea Investment Management AB raised its stake in Zoetis by 10.0% in the second quarter. Nordea Investment Management AB now owns 2,356,166 shares of the company’s stock valued at $368,245,000 after buying an additional 214,889 shares in the last quarter. Finally, Empirical Asset Management LLC lifted its holdings in Zoetis by 25.6% during the 2nd quarter. Empirical Asset Management LLC now owns 4,109 shares of the company’s stock worth $641,000 after buying an additional 838 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Up 0.6%

Shares of NYSE:ZTS opened at $144.15 on Friday. Zoetis Inc. has a 1-year low of $139.34 and a 1-year high of $193.49. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04. The stock has a market cap of $63.88 billion, a P/E ratio of 24.81, a P/E/G ratio of 2.30 and a beta of 0.90. The firm has a fifty day moving average price of $148.73 and a 200 day moving average price of $153.76.

Zoetis (NYSE:ZTS) last announced its earnings results on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, beating analysts’ consensus estimates of $1.62 by $0.14. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The business had revenue of $2.46 billion during the quarter, compared to analysts’ expectations of $2.41 billion. During the same period in the prior year, the company earned $1.56 earnings per share. The business’s revenue was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Sell-side analysts predict that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 2nd. Shareholders of record on Friday, October 31st will be paid a $0.50 dividend. This represents a $2.00 annualized dividend and a dividend yield of 1.4%. The ex-dividend date is Friday, October 31st. Zoetis’s dividend payout ratio (DPR) is 34.42%.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the company. Leerink Partners lowered Zoetis from an “outperform” rating to a “market perform” rating and cut their target price for the stock from $180.00 to $155.00 in a research report on Thursday, July 17th. Weiss Ratings reissued a “hold (c-)” rating on shares of Zoetis in a report on Wednesday, October 8th. Piper Sandler upped their target price on shares of Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a report on Monday, August 11th. Leerink Partnrs lowered shares of Zoetis from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 17th. Finally, Argus reissued a “buy” rating and issued a $190.00 price target on shares of Zoetis in a research report on Tuesday, September 9th. Four investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat, Zoetis presently has a consensus rating of “Hold” and an average price target of $196.71.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.